Citius Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Citius Pharmaceuticals's earnings have been declining at an average annual rate of -19.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-19.6%
Earnings growth rate
31.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -44.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
Apr 06
We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate
Dec 08Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?
Aug 01We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Apr 12Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation
Dec 25Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK
Sep 28Citius Pharmaceuticals GAAP EPS of -$0.06
Aug 11Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely
Aug 05Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK
Jul 12Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Jul 05Critical Care Biopharma - Citius Pharmaceuticals
Apr 13Citius: 2022 Is A Year Of Catalysts
Mar 28We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Dec 04Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization
Sep 26Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth
Aug 28Citius: Halt For Superiority On The Horizon
Jun 15We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
May 15Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results
Apr 26Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?
Dec 18Revenue & Expenses Breakdown
How Citius Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -40 | 29 | 12 |
| 31 Mar 24 | 0 | -37 | 26 | 13 |
| 31 Dec 23 | 0 | -39 | 25 | 14 |
| 30 Sep 23 | 0 | -34 | 22 | 15 |
| 30 Jun 23 | 0 | -31 | 18 | 16 |
| 31 Mar 23 | 0 | -31 | 17 | 17 |
| 31 Dec 22 | 0 | -28 | 16 | 16 |
| 30 Sep 22 | 0 | -34 | 16 | 18 |
| 30 Jun 22 | 0 | -31 | 15 | 16 |
| 31 Mar 22 | 0 | -29 | 15 | 13 |
| 31 Dec 21 | 0 | -26 | 13 | 12 |
| 30 Sep 21 | 0 | -25 | 11 | 12 |
| 30 Jun 21 | 0 | -24 | 11 | 11 |
| 31 Mar 21 | 0 | -21 | 9 | 12 |
| 31 Dec 20 | 0 | -21 | 9 | 12 |
| 30 Sep 20 | 0 | -18 | 9 | 9 |
| 30 Jun 20 | 0 | -17 | 8 | 9 |
| 31 Mar 20 | 0 | -17 | 8 | 9 |
| 31 Dec 19 | 0 | -16 | 7 | 9 |
| 30 Sep 19 | 0 | -16 | 7 | 9 |
| 30 Jun 19 | 0 | -15 | 7 | 8 |
| 31 Mar 19 | 0 | -12 | 7 | 6 |
| 31 Dec 18 | 0 | -13 | 6 | 8 |
| 30 Sep 18 | 0 | -13 | 7 | 7 |
| 30 Jun 18 | 0 | -13 | 7 | 5 |
| 31 Mar 18 | 0 | -13 | 8 | 5 |
| 31 Dec 17 | 0 | -11 | 8 | 2 |
| 30 Sep 17 | 0 | -10 | 7 | 3 |
| 30 Jun 17 | 0 | -10 | 7 | 4 |
| 31 Mar 17 | 0 | -11 | 6 | 5 |
| 31 Dec 16 | 0 | -9 | 5 | 4 |
| 30 Sep 16 | 0 | -8 | 5 | 3 |
| 30 Jun 16 | 0 | -7 | 3 | 2 |
| 31 Mar 16 | 0 | -4 | 2 | 2 |
| 31 Dec 15 | 0 | -3 | 1 | 2 |
| 30 Sep 15 | 0 | -3 | 1 | 2 |
| 30 Jun 15 | 0 | -3 | 2 | 1 |
| 31 Mar 15 | 0 | -2 | 1 | 1 |
| 31 Dec 14 | 0 | -2 | 1 | 0 |
| 30 Sep 14 | 0 | -1 | 1 | 0 |
| 30 Jun 14 | 0 | -1 | 0 | 0 |
| 31 Mar 14 | 0 | -1 | 0 | 0 |
Quality Earnings: CTXR is currently unprofitable.
Growing Profit Margin: CTXR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CTXR is unprofitable, and losses have increased over the past 5 years at a rate of 19.6% per year.
Accelerating Growth: Unable to compare CTXR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTXR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: CTXR has a negative Return on Equity (-44.38%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 13:26 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Citius Pharmaceuticals, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Jason Kolbert | H.C. Wainwright & Co. |
| Vernon Bernardino | H.C. Wainwright & Co. |